Compare Inovio Pharmaceuticals Inc (INO) vs Ternium S.A. Ternium S.A. American Depositary Shares (each representing ten shares USD1.00 par value) (TX) Price & Performance
Price performance (Past 24H)
Key statistics
Key statistics
Inovio Pharmaceuticals Inc vs Ternium S.A. Ternium S.A. American Depositary Shares (each representing ten shares USD1.00 par value) — how do they compare? Inovio Pharmaceuticals Inc trades at $1.18 (market cap $103.19M), while Ternium S.A. Ternium S.A. American Depositary Shares (each representing ten shares USD1.00 par value) trades at $58.55 (market cap $11.58B). The key difference: Ternium S.A. Ternium S.A. American Depositary Shares (each representing ten shares USD1.00 par value) is far larger — about 112.2× Inovio Pharmaceuticals Inc's market cap, and Ternium S.A. Ternium S.A. American Depositary Shares (each representing ten shares USD1.00 par value) pays a 3.73% dividend while Inovio Pharmaceuticals Inc pays none. Which is the better fit depends on your goals — on Pluang, investors hold Inovio Pharmaceuticals Inc for 43 Days and Ternium S.A. Ternium S.A. American Depositary Shares (each representing ten shares USD1.00 par value) for 0 Days on average.
| INO | TX | |
|---|---|---|
Market Cap | $103.19M | $11.58B |
Volume | 8,461,580 | 456,367 |
Sector | Health | Basic Materials |
52-Week High | $2.60 | $58.99 |
52-Week Low | $0.66 | $35.26 |
Typical Hold Time | 43 Days | 0 Days |
Enterprise Value | $74.52M | $11.90B |
Dividend Yield | — | 3.73% |
Aura AI Summary
Signals from Pluang's Aura AI — not financial advice
Aura AI Summary
Signals from Pluang's Aura AI — not financial advice
Inovio Pharmaceuticals (INO) trades at $0.986, down 10.77% in the last session, with a bearish technical signal from moving averages. The company shows consistent quarterly earnings beats but operates with minimal revenue ($65K in 2025) and significant losses (-$85M net income). Key catalyst is the October 30, 2026 FDA decision on INO-3107 for recurrent respiratory papillomatosis. Analyst consensus remains positive with a $2.75 price target despite negative profitability metrics.
The stock presents high-risk biotech speculation with potential upside dependent on FDA approval. Current valuation metrics (P/S 961.51) reflect speculative optimism rather than fundamentals. Major risks include cash burn (-$21.5M net cash flow), regulatory uncertainty, and competitive pressures. Successful commercialization of INO-3107 is critical for viability.
Ternium (TX) trades at $58.99, up 1.81% with strong Q2 2026 earnings beating estimates by 43%. The stock shows solid fundamentals with attractive valuation metrics including P/E of 16.39 and P/S of 0.72. Recent analyst upgrades to Strong Buy highlight improving sentiment as Mexico's steel recovery drives operational momentum and the $4B Pesqueria project promises future capacity growth.
The stock offers value with 7% dividend yield projections and 14.5% upside to $65.52 fair value. Key risks include steel price volatility and trade uncertainty, but declining CapEx should boost free cash flow above 15% yield. Analyst consensus at $57.17 with 50% Buy ratings supports cautious optimism for continued recovery.
Returns comparison
Trailing returns across standard periods
Returns comparison
Trailing returns across standard periods
Investor sentiment on Pluang
What Pluang investors did over the last 30 days
Investor sentiment on Pluang
What Pluang investors did over the last 30 days
About Inovio Pharmaceuticals Inc
Inovio Pharmaceuticals Inc is a United States based biotechnology company that develops active DNA-based immunotherapies and vaccines to treat and prevent cancers and infectious diseases. The company is engaged in gene therapy, where its immunotherapy platform consists of DNA-based immunotherapy and electroporation delivery technologies.
Read more on INO →About Ternium S.A. Ternium S.A. American Depositary Shares (each representing ten shares USD1.00 par value)
Ternium S.A. is a Luxembourg-headquartered steel producer operating an integrated production system, from mining through finished flat and long steel products. It runs 18 production plants and two mining operations across Argentina, Brazil, Colombia, Guatemala, Mexico, and US, serving the automotive, construction, appliance, and energy industries.
Read more on TX →
